Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03018067 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia
A Phase 2 study, sponsored by Ardelyx.
- Terminated
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT03018067 is a Phase 2 study that was terminated before completion, run by Ardelyx. The registered enrollment target is 60 participants.
The verdict
NCT03018067, a Phase 2 study, was terminated before completion, sponsored by Ardelyx.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This phase 2, single-blind, placebo-controlled study will evaluate the onset-of-action, safety, and efficacy of RDX227675 for the treatment of hyperkalemia. Subjects who qualify are randomized into one of four treatment groups: Group 1 (Placebo qd), Group 2 (RDX227675 10 g qd), Group 3 (RDX227675 20 g qd), Group 4 (RDX227675 30 g qd).
Interventions
- DRUG Placebo
- DRUG RDX227675
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03018067
The ClinicalTrials.gov registry entry for NCT03018067 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardelyx, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03018067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03018067 about?
NCT03018067 is a clinical study titled "A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia". This phase 2, single-blind, placebo-controlled study will evaluate the onset-of-action, safety, and efficacy of RDX227675 for the treatment of hyperkalemia. Subjects who qualify are randomized into one of four treatment groups: Group 1 (Placebo qd), Group 2 (RDX227675 10 g qd), Group 3 (RDX227675 20...
What is the current status of trial NCT03018067?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2017-01. Estimated completion is 2017-05.
What interventions are being tested in trial NCT03018067?
The interventions under investigation include: Placebo (DRUG), RDX227675 (DRUG).
Who is sponsoring clinical trial NCT03018067?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.